MedTrace Logo

Evaluating an Ebola and a Marburg Vaccine in Uganda

NCT00997607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2013-01-28

No results posted yet for this study

Summary

This study will test two new vaccines, one for Ebola and one for Marburg virus, to see if they are safe, if they have side effects, and if they create an immune response in people who receive them.

Conditions

  • Ebola Virus Disease
  • Marburg Virus Disease

Interventions

BIOLOGICAL

Ebola vaccine

4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8

BIOLOGICAL

Marburg vaccine

4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8

OTHER

Placebo injection

4 mg of saline injection delivered at Weeks 0, 4, and 8

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Hannah Kibuuka, MBChB, MMed, MPH · Makerere University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997607 on ClinicalTrials.gov